The tyrosine kinase inhibitor imatinib (Glivec) appears to prevent chronic myeloid leukaemia from progressing a decade into treatment – with no signs of additional long-term toxicity a follow-up study finds. Of more than 500 chronic myeloid leukaemia (CML) patients given imatinib as their initial therapy, just over 83% had survived the disease 10 years later, ...
Early excitement seen with imatinib remains a decade on
By Sunalie Silva
16 Mar 2017